Research programme: anticancer prodrugs - Threshold Pharmaceuticals

Drug Profile

Research programme: anticancer prodrugs - Threshold Pharmaceuticals

Alternative Names: HAP; Hypoxia-activated prodrug technology - Threshold; TH-3424

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Threshold Pharmaceuticals
  • Developer National Cancer Institute (USA); Threshold Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action AKR1C3 protein inhibitors; Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatocellular carcinoma; Solid tumours
  • Research Acute lymphoblastic leukaemia

Most Recent Events

  • 19 Dec 2016 Early research in Acute lymphoblastic leukaemia in Australia (unspecified route)
  • 29 Sep 2016 Threshold Pharmaceuticals plans a phase I trial for TH 3424 for Solid tumours in 2017
  • 25 Apr 2016 Preclinical trials in Hepatocellular carcinoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top